Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.
Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refract...
Κύριοι συγγραφείς: | Morel, A, Talbot, D |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Dove Medical Press Ltd.
2010
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use
ανά: A. A. Gritskevich, κ.ά.
Έκδοση: (2022-06-01) -
From clinical trials to the front line: Vinflunine for Treatment of UrothelialCell Carcinoma at the National Cancer Institute of Naples
ανά: GAETANO eFACCHINI, κ.ά.
Έκδοση: (2016-05-01) -
Vinflunine in the treatment of bladder cancer
ανά: Mark Bachner, κ.ά.
Έκδοση: (2008-11-01) -
A Prospective Study of I.V. Vinflunine in the Treatment of Patients with Advanced or Metastatic Urothelial Carcinoma after Failure of a Platinum-containing Regimen and Biomarker Correlates
ανά: Fatma M.A. Abouelkasem, κ.ά.
Έκδοση: (2022-08-01) -
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
ανά: Rodolfo Passalacqua, κ.ά.
Έκδοση: (2017-07-01)